tulisokibart, Placebo to Subcutaneous or intravenous MK-7240 (Tulisokibart), tulisokibart
MK-7240-008
Phase 3 small_molecule active
Quick answer
tulisokibart, Placebo to Subcutaneous or intravenous MK-7240 (Tulisokibart), tulisokibart for Crohn’s Disease is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Crohn’s Disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active